Oxytocin and Reward Processing in Women

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorInternational Research Training Group 2804

About this trial

Oxytocin is a hypothalamic neuropeptide that is best known for its peripheral physiological effects in the female organism i.e., uterine contractions during birth. The neuropeptide furthermore affects reward processing and metabolic functions such as eating behavior and body weight. Oxytocin receptors are present in brain regions associated with the processing of rewards, e.g., ventral tegmental area (VTA), nucleus accumbens (NAcc) and nucleus stria terminalis.

Previous studies indicate that oxytocin interacts with sex hormones such as estradiol in a sex-specific manner. Despite known sex differences in oxytocin function, most studies i.e., on the metabolic effects of oxytocin in humans have so far focused on young, healthy men.

Intranasal oxytocin administration has emerged as a method to experimentally investigate central nervous effects of oxytocin in the absence of relevant side effects.

In the proposed study the investigators aim to systematically investigate the acute effect of intranasal oxytocin on reward processing in relation to circulating and synthetic sex hormones in healthy, naturally cycling women and in women taking hormonal oral contraceptive pills. The investigators will administer 24 international units (IU) of intranasal oxytocin vs. placebo and investigate neural correlates in a 3T MRI scanner including functional imaging during a reward processing task, changes in brain anatomy and connectivity. Additionally, metabolic functions, eating behavior and changes in mood and wellbeing will be assessed and blood will be drawn to assess parameters of hormonal and metabolic status.

Eligibility criteria

Qualifiers

Body-mass index (BMI): 18-28 kg/m2

Sex: female (since birth)

Normal or corrected vision

Natural menstrual cycle (NC) or intake of hormonal oral contraceptives (OC)

Disqualifiers

No German language fluency (due to German language test content)

Smoking

Medication taken within the last 6 weeks (except for OCs in the respective group)

Current neurological or psychiatric disease (anamnestic survey)

Trial design

Treatments tested in this trial

  • Intranasal oxytocin administration
  • Intranasal placebo administration

Treatment groups

100 Participants
are divided into 4 treatment groups

Sponsors and collaborators

International Research Training Group 2804

Lead sponsor

University Hospital Tuebingen

Collaborator

German Research Foundation

Collaborator

Uppsala University

Collaborator